SCHEMBL26601883

SCHEMBL26601883

Cc1nc(Cl)cc(OCc2ccccc2)c1C(O)CN

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ HTT P42858 3/20 0.44
▸ SMN1; SMN2 Q16637 2/20 0.44
▸ STAT3 P40763 1/20 0.44
▸ L3MBTL1 Q9Y468 3/20 0.41
▸ LMNA P02545 2/20 0.41
▸ MAPT P10636 2/20 0.41
▸ RHEB Q15382 1/20 0.41
▸ MCL1 Q07820 1/20 0.40
▸ ATP4A P20648 2/20 0.39
▸ ATP4B P51164 2/20 0.39
▸ PLAU P00749 1/20 0.39
▸ MAPK1 P28482 2/20 0.39
▸ TSHR P16473 2/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ HPGD P15428 1/20 0.39
▸ TDP1 Q9NUW8 1/20 0.39
▸ LIPE Q05469 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30593159 1.00 HTT (0.44) HTTSMN1; SMN2STAT3L3MBTL1LMNA
SCHEMBL31517782 0.84 HTT (0.47) HTTSMN1; SMN2STAT3L3MBTL1LMNA
SCHEMBL26601636 0.83 HTT (0.44) HTTSMN1; SMN2STAT3L3MBTL1LMNA
SCHEMBL26601889 0.80 MAPK1 (0.46) HTTSMN1; SMN2STAT3MCL1MAPK1
SCHEMBL30593116 0.80 MAPK1 (0.46) HTTSMN1; SMN2STAT3MCL1MAPK1
SCHEMBL26601602 0.78 SMN1; SMN2 (0.44) HTTSMN1; SMN2STAT3L3MBTL1LMNA
SCHEMBL26601702 0.78 HTT (0.51) HTTSMN1; SMN2STAT3L3MBTL1LMNA
SCHEMBL26601820 0.77 HTT (0.54) HTTSMN1; SMN2STAT3L3MBTL1LMNA
SCHEMBL4781292 0.77 HTT (0.54) HTTSMN1; SMN2STAT3L3MBTL1LMNA
SCHEMBL31517865 0.76 HTT (0.49) HTTSMN1; SMN2STAT3L3MBTL1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250388541-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN VERTEX PHARMACEUTICALS INCORPORATED (US) 2025-12-25 — — US disclosed
US-20250388543-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN VERTEX PHARMACEUTICALS INCORPORATED (US) 2025-12-25 — — US disclosed
EP-4511115-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN Vertex Pharmaceuticals Incorporated (US) 2025-02-26 — — EP disclosed
WO-2023205465-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-10-26 — — WO disclosed
WO-2023205465-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-10-26 — — WO disclosed
WO-2023205468-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-10-26 — — WO disclosed
WO-2023205468-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-10-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250388543-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN SCN8A, SCN1B, SCN3A HTT 2180/4885SMN1; SMN2 738/4885STAT3 4427/4885
US-20250388541-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN SCN1B, CLIC1, HCN1 HTT 1485/4885SMN1; SMN2 760/4885STAT3 3474/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback